Ochsner Health physicians Dr. Richard Zweifler and Dr. Joseph Tarsia are co-authors on a post hoc analysis carried out in the ...

Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week ...

The drugs related to the highest industry payments were blood thinners rivaroxaban (brand name Xarelto) and apixaban (brand ...

Apixaban is a generic oral tablet that’s prescribed for certain types of blood clots. It’s available as the brand-name drug Eliquis. The cost of apixaban, with and without insurance ...

Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Participants were survivors of acute ischemic strokes likely related to their Afib. In the hospital stroke unit, they were ...

Is there something comparable that is less expensive? — D.C. Answer: Apixaban (Eliquis) is one of the new oral anticoagulant drugs, often abbreviated “NOACs.” They are effective and have ...

and Apixaban (Eliquis).” Aspirin, a pretty common medication, is an antiplatelet, which prevents platelets from clumping together to form a clot and is often prescribed to people who have had a heart ...

Further trials comparing aspirin with newer anticoagulants (dabigatran, apixaban and rivaroxaban) are necessary to assess the role of each agent in stroke prevention in patients with AF.

Rivaroxaban and apixaban, both NOACs, exert their anticoagulant effects via a different mechanism than that of dabigatran. These drugs work by directly inhibiting factor Xa in the coagulation cascade.

The findings of this post hoc analysis suggest that both apixaban and aspirin may be effective in preventing adverse clinical outcomes in patients with a history of cancer and cryptogenic stroke.